Compare Liraglutide (evidence A) and Lixisenatide (evidence A) on mechanism, clinical status, safety, and dosing.
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is…
Lixisenatide is a once-daily GLP-1 receptor agonist (MW ~4858.5 g/mol) based on the exendin-4 scaffold, with a modified C-terminal tail containing six lysine…
Full profiles: Liraglutide, Lixisenatide.